Neon Therapeutics,develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen,S. Lander, Robert Schreiber, Ton Schumacher and Catherineon October 21, 2013 and is headquartered in Cambridge, MA.SHORT INTEREST690.08/15/19P/E Current-0.46 P/E Ratio (with extraordinary items)-0.8Average Recommendation: BUYAverage Target Price: 17.78